(CC-5013-CLL-009) A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Study of the Safety and Efficacy of Different Lenalidomide (Revlimid) Dose Regimens in Subjects with Relapsed or Refractory B-Cell Chronic...
Title (CC-5013-CLL-009) A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Study of the Safety and Efficacy of Different Lenalidomide (Revlimid) Dose Regimens in Subjects with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Contact CB
Principal Investigator Myron Czuczman, MD
Study Number 157109
Phase2
Summary
To evaluate the safety of different lenalidomide dose regimens in subjects with relapsed or refractory B-Cell CLL.
Eligibility
-
Age greater than or equal to 18 years at the time of signing the informed consent form
-
Must understand and voluntarily sign an informed consent form.
-
Must have a documented diagnosis of B-Cell CLL.
- Must be relapsed or refractory to a least 1 but no more than 3 prior regimen(s) for treatment of CLL. At least one of the prior treatments must have included a purine analog-based regimen.
- Must be able to adhere to the study visit schedule and other protocol requirements.
